Women's Health March 28, 2026 0 Comments

Pfizer Drops a Game-Changer: Could This New Lyme Disease Vaccine Be the Ultimate Health Hack You’ve Been Waiting For?

Ever wonder why those tiny deer ticks seem to have the upper hand in the battle against humans? Well, for decades, Lyme disease has been sneaking into our lives, turning outdoor fun into a risk-filled adventure. But this week, something big dropped: Pfizer and Valneva unveiled phase 3 clinical trial data for a new Lyme disease vaccine, PF-0730740, boasting about 70% effectiveness after four doses. Sure, 70% might not sound like a knockout punch, but considering half a million Americans get bitten by this sneaky bacterium each year, this vaccine could be a game-changer—especially for those who live where ticks are basically unwelcome party crashers. Before you lace up your hiking boots or hit the golf course, let’s dive into what this means, why the previous vaccine vanished, and whether you really need to roll up your sleeve for these shots. LEARN MORE.

4 min read

This week, Pfizer and French vaccine company, Valneva, released phase 3 clinical trial data for PF-0730740, a four-dose Lyme disease vaccine they developed together that is about 70% effective.

Lyme disease impacts nearly half a million Americans each year, making this the most common vector-borne illness in the country. It is caused by Borrelia burgdorferi, a bacterium transmitted by deer ticks, which can live in tall grass. The disease is named after the town in which it was first discovered in the 1970s: Lyme, Connecticut. And though it is often associated with New England, cases have been reported in all 50 states, as well as in Europe and Asia.

While an earlier Lyme disease vaccine for humans was released in the 90s, there is currently no vaccine available in the U.S. (more on this in a bit). Here’s what infectious disease doctors want you to know.

Meet the experts: Amesh A. Adalja, MD, is a senior scholar at the Johns Hopkins Center for Health Security; Thomas Russo, MD, is a professor and chief of infectious diseases at the University at Buffalo in New York.

What do we know about the new vaccine?

PF-0730740 is given in four doses: The first two doses are given two months apart, the third dose is given between months five and nine, and the fourth and final dose is given a year later. In people who received all four shots, the vaccine was about 70 percent effective at preventing Lyme disease. The clinical trial included participants aged 5 and older across the U.S., Canada, and Europe.

While no vaccine is 100 percent effective at preventing illness, an effectiveness of around 70 percent seems less than ideal.

“It’s not optimal, obviously,” says Thomas Russo, MD, a professor and chief of Infectious Diseases at the University at Buffalo in New York. “But it’s certainly better than nothing for people who are in a high-risk area and are engaged in high-risk activities.” Some of these high-risk activities include hiking, gardening, golfing, camping, or other outdoor activities.

It’s also unclear whether the vaccine would reduce the risk of Lyme disease complications, such as central nervous system issues or cardiac complications, Russo adds. “It may be that the 30 percent of people who still get Lyme disease have a much milder course of illness and fewer complications, but we don’t know yet,” he says.

Still, Amesh A. Adalja, MD, a senior scholar at the Johns Hopkins Center for Health Security, says that 70 percent is still “fairly high” and can provide “significant protection” to people who are vaccinated. (For what it’s worth, the seasonal flu vaccine is around 40 to 60 percent effective each year and usually worth getting.)

Wait, what happened with the first Lyme vaccine?

The first Lyme disease vaccine, Lymerix, was approved by the FDA in 1998. It reduced new infections in vaccinated adults by nearly 80 percent, but just three years later, the manufacturer pulled the vaccine from the market.

“Lymerix’s manufacturer ceased marketing the vaccine after it had very poor uptake and was falsely associated with certain adverse reactions,” Adalja says.

The vaccine also required three doses—given a month apart and then a year later—and was “tepidly recommended” by the Centers for Disease Control and Prevention (CDC), which made it less appealing to the general public, adds Russo.

And if you’re wondering why it’s important to note that Pfizer’s new vaccine is a human Lyme disease vaccine, it’s because dogs have had access to their own version for years. But Russo points out that dog vaccines usually have less stringent requirements than those for humans and are regulated by the USDA rather than the FDA.

Common signs and symptoms of Lyme disease

Lyme disease can cause a range of symptoms, and people may experience different signs depending on how long it’s been since they were infected, per the CDC. Some of the most common symptoms that can appear within the first 30 days since being bitten by an infected tick include:

Fever
Chills
Headache
Fatigue
Muscle and joint aches
Swollen lymph nodes
Erythema migrans rash (aka bullseye rash)

You may also have the following symptoms days to months after you’ve been infected if your Lyme disease isn’t treated, according to the CDC:

Severe headaches and neck stiffness
Rashes on other areas of the body
Facial palsy
Arthritis with severe joint pain and swelling
Intermittent pain in tendons, muscles, joints, and bones
Heart palpitations or an irregular heartbeat (called Lyme carditis)
Episodes of dizziness or shortness of breath
Inflammation of the brain and spinal cord
Nerve pain
Shooting pains, numbness, or tingling in the hands or feet

How does Lyme disease differ from post-treatment Lyme disease syndrome?

“Lyme disease is an acute infectious disease that has distinct stages, signs, and symptoms,” Adalja says, adding that there is a specific diagnostic test for Lyme disease.

But there’s also something called post-treatment Lyme disease syndrome (which some people refer to as “chronic Lyme”). “Post-treatment Lyme disease syndrome is an entity that is poorly understood, but seems to occur in a minority of individuals who have persistent symptoms, despite adequate antibiotic treatment,” Adalja says. “There is no diagnostic test or established treatment for it.”

Does everyone need to get this new vaccine?

Probably not, according to infectious disease doctors, unless you’re at risk geographically. “Lyme disease risk is geographic, so those individuals who live in Lyme-endemic areas would be where the vaccine would have [the most] benefit,” Adalja says.

In the meantime, you can always rely on old-school ways to lower your risk of Lyme disease: wear insect repellent, cover skin with long-sleeved shirts, long pants, and tuck pants into your socks, and always make sure to check for ticks after being outside.

If you suspect you may have been exposed to Lyme disease from a tick bite, reach out to a medical provider as soon as possible. Early detection and antibiotic treatment are key.

Korin Miller is a freelance writer specializing in general wellness, sexual health and relationships, and lifestyle trends, with work appearing in Men’s Health, Women’s Health, Self, Glamour, and more. She has a master’s degree from American University, lives by the beach, and hopes to own a teacup pig and taco truck one day.